局限性前列腺癌三周高度大分割调强放疗前瞻性研究的长期结局
本前瞻性先导研究于2014年4月至2015年9月纳入25例低至中危前列腺癌患者,其中24例接受54 Gy/15次(每次3.6 Gy)三周高度大分割调强放疗(IMRT),不置入前列腺内基准标记或直肠水凝胶间隔物,新辅助激素治疗4至8个月。中位随访77个月,5年生化无复发生存率91.7%、临床无复发生存率95.8%、总生存率95.8%,7年分别为87.5%、86.3%、95.8%。未观察到≥2级晚期胃肠毒性或≥3级晚期泌尿生殖毒性,2级泌尿生殖毒性5年累积发生率8.5%、7年18.3%。作者认为该方案可能是中度大分割的替代选择,但需进一步验证。
要点
- 24例低至中危前列腺癌接受54 Gy/15次三周IMRT,中位随访77个月。
- 5年生化无复发生存率91.7%、临床无复发生存率95.8%、总生存率95.8%。
- 未观察到≥2级晚期胃肠毒性或≥3级晚期泌尿生殖毒性,2级泌尿生殖毒性7年累积发生率18.3%。
核心结论
- 三周54 Gy/15次高度大分割IMRT不置入前列腺内基准标记可获得良好肿瘤学结局且无严重并发症,作者认为可能是中度大分割的替代选择,但需进一步验证。
研究设计与样本
- 前瞻性先导研究,2014年4月至2015年9月纳入25例低至中危前列腺癌患者,其中24例接受高度大分割IMRT。
- 放疗方案为54 Gy/15次(每次3.6 Gy)三周,使用IMRT,不置入前列腺内基准标记或直肠水凝胶间隔物。
- 新辅助激素治疗4至8个月,中位持续时间5.3个月;未给予任何患者辅助激素治疗。
- 分析生化无复发生存率、临床无复发生存率、总生存率及晚期≥2级毒性累积发生率。
主要发现
- 24例治疗患者中17%为低危、83%为中危;中位随访77个月(范围57至87个月)。
- 5年生化无复发生存率91.7%、临床无复发生存率95.8%、总生存率95.8%。
- 7年生化无复发生存率87.5%、临床无复发生存率86.3%、总生存率95.8%。
- 未观察到≥2级晚期胃肠毒性,也未观察到≥3级晚期泌尿生殖毒性。
- 2级泌尿生殖毒性累积发生率5年为8.5%、7年为18.3%。
临床怎么用
- 作者认为该三周高度大分割IMRT方案可能是中度大分割的替代选择,但需进一步验证。
局限性
- 作者指出需进一步验证(further validation is needed)。
- 原文标题与摘要写明为先导研究(pilot study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reports of radiation therapy for prostate cancer using dose fractions between moderate hypofractionation and ultrahypofractionation are limited. This pilot study involved the application of highly hypofractionated intensity modulated radiation therapy (IMRT) in 15 fractions for 3 weeks and the number of fractions was intermediate between the 2 previously mentioned dose fractions. The long-term outcomes are reported. METHODS AND MATERIALS: From April 2014 to September 2015, patients with low- to intermediate-risk prostate cancer received 54 Gy in 15 fractions (3.6 Gy per fraction) for 3 weeks using IMRT without intraprostatic fiducial markers or a rectal hydrogel spacer. Neoadjuvant hormone therapy (HT) was administered for 4 to 8 months. Adjuvant HT was not administered to any patients. Rates of biochemical relapse-free survival, clinical relapse-free survival, overall survival, and the cumulative incidence of late grade ≥2 toxicities were analyzed. RESULTS: Twenty-five patients were enrolled in this prospective study; 24 of them were treated with highly hypofractionated IMRT (17% had low-risk and 83% had intermediate-risk disease). The median neoadjuvant HT duration was 5.3 months. The median follow-up period was 77 months (range, 57-87 months). Biochemical relapse-free survival, clinical relapse-free survival, and overall survival rates were 91.7%, 95.8%, and 95.8% at 5 years, and 87.5%, 86.3%, and 95.8% at 7 years, respectively. Neither grade ≥2 late gastrointestinal toxicity nor grade ≥3 late genitourinary toxicity was observed. The cumulative incidence rates of grade 2 genitourinary toxicity were 8.5% and 18.3% at 5 and 7 years, respectively. CONCLUSIONS: Highly hypofractionated IMRT delivering 54 Gy in 15 fractions for 3 weeks for prostate cancer without intraprostatic fiducial markers facilitated favorable oncological outcomes without severe complications. This treatment approach may be a possible alternative to moderate hypofractionation, but further validation is needed.
引用
- Nakamura K, Ikeda I, Inokuchi H, et al. Long-Term Outcomes of a Prospective Study on Highly Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer for 3 Weeks. Pract Radiat Oncol. 2023. PMID: 37414247. doi:10.1016/j.prro.2023.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。